Generic Name and Formulations:
Lidocaine 5%; adhesive patch.
Indications for LIDODERM:
Apply to intact skin, covering most painful area. To adjust dose, cut patches before removing release liner. Remove if irritation or burning occurs; do not reapply until irritation subsides. May apply up to 3 patches at once for up to 12hrs of a 24-hour period. Hepatic impairment or debilitated: use smaller treatment areas.
Do not apply to broken or inflamed skin. Avoid eyes, mucous membranes, longer duration of application, and application of more than 3 patches. Do not ingest; may be toxic to children and pets. Hepatic disease. Small patients. Pregnancy (Cat.B). Labor & delivery. Nursing mothers.
Toxicity may be potentiated by Class I antiarrhythmics (e.g., tocainide, mexiletine). Additive effects with other local anesthetics.
Local effects (e.g., erythema, edema), allergic reactions (e.g., urticaria, angioedema, bronchospasm).
Patches (10cm x 14cm)—30
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Larotrectinib: Promising for All TRK-Positive Tumors
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- NSCLC: Stratifying Patients With Complex EGFR Mutations